SI3814347T1 - Naftiridinonske spojine uporabne kot T celični aktivatorji - Google Patents
Naftiridinonske spojine uporabne kot T celični aktivatorjiInfo
- Publication number
- SI3814347T1 SI3814347T1 SI201930549T SI201930549T SI3814347T1 SI 3814347 T1 SI3814347 T1 SI 3814347T1 SI 201930549 T SI201930549 T SI 201930549T SI 201930549 T SI201930549 T SI 201930549T SI 3814347 T1 SI3814347 T1 SI 3814347T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compounds useful
- cell activators
- naphthyridinone compounds
- naphthyridinone
- activators
- Prior art date
Links
- 229940126530 T cell activator Drugs 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690444P | 2018-06-27 | 2018-06-27 | |
| EP19740166.4A EP3814347B1 (en) | 2018-06-27 | 2019-06-26 | Naphthyridinone compounds useful as t cell activators |
| PCT/US2019/039131 WO2020006016A1 (en) | 2018-06-27 | 2019-06-26 | Naphthyridinone compounds useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3814347T1 true SI3814347T1 (sl) | 2023-07-31 |
Family
ID=67297314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930549T SI3814347T1 (sl) | 2018-06-27 | 2019-06-26 | Naftiridinonske spojine uporabne kot T celični aktivatorji |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11866430B2 (sl) |
| EP (1) | EP3814347B1 (sl) |
| JP (1) | JP7373512B2 (sl) |
| KR (1) | KR20210024587A (sl) |
| CN (1) | CN112585139B (sl) |
| AU (1) | AU2019291792B2 (sl) |
| BR (1) | BR112020026568A2 (sl) |
| CA (1) | CA3104647A1 (sl) |
| DK (1) | DK3814347T3 (sl) |
| EA (1) | EA202190137A1 (sl) |
| ES (1) | ES2950007T3 (sl) |
| FI (1) | FI3814347T3 (sl) |
| HR (1) | HRP20230627T1 (sl) |
| HU (1) | HUE062412T2 (sl) |
| IL (1) | IL279730B2 (sl) |
| LT (1) | LT3814347T (sl) |
| MX (1) | MX2020013373A (sl) |
| PL (1) | PL3814347T3 (sl) |
| PT (1) | PT3814347T (sl) |
| RS (1) | RS64285B1 (sl) |
| SG (1) | SG11202012973RA (sl) |
| SI (1) | SI3814347T1 (sl) |
| WO (1) | WO2020006016A1 (sl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| BR112022010112A2 (pt) | 2019-11-28 | 2022-09-06 | Bayer Ag | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica |
| CA3162767A1 (en) | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| EP4065584A1 (en) | 2019-11-28 | 2022-10-05 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| KR20220118481A (ko) * | 2019-12-19 | 2022-08-25 | 브리스톨-마이어스 스큅 컴퍼니 | Dgk 억제제 및 체크포인트 길항제의 조합물 |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| MX2022007130A (es) * | 2019-12-23 | 2022-07-11 | Bristol Myers Squibb Co | Derivados de piperazina sustituidos utiles como activadores de celulas t. |
| IL294273A (en) * | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted heteroaryl compounds are useful as t-cell activators |
| CR20220303A (es) | 2019-12-24 | 2022-09-02 | Gilead Sciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
| EP4139286A1 (en) | 2020-04-24 | 2023-03-01 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| US20240067645A1 (en) * | 2020-11-26 | 2024-02-29 | Lg Chem, Ltd. | Heterocyclic compound as diacylglycerol kinase inhibitor and use thereof |
| EP4262986A1 (en) | 2020-12-16 | 2023-10-25 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| AU2022297367A1 (en) * | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222439A1 (en) * | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023150186A1 (en) * | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| WO2023165528A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| CN118871438A (zh) | 2022-03-01 | 2024-10-29 | 英矽智能科技知识产权有限公司 | 二酰基甘油激酶(DGK)α抑制剂及其用途 |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| WO2024026076A2 (en) * | 2022-07-29 | 2024-02-01 | Septerna, Inc. | Substituted 3,4-dihydroquinolinone inhibitors of tshr |
| WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024165468A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combination of ccr8 antibodies with dgk inhibitors in the treatment of cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| RU2005102004A (ru) | 2002-06-27 | 2005-10-20 | Шеринг Акциенгезельшафт (De) | Замещенные хинолины как антагонисты рецептора ccr5 |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| JP2006521400A (ja) | 2003-03-26 | 2006-09-21 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び関連障害の処置のための化合物及びそれらの使用 |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| WO2005009967A2 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| WO2005021546A1 (en) | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| ME02461B (me) | 2005-05-10 | 2017-02-20 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| EP1907424B1 (en) | 2005-07-01 | 2015-07-29 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP2064207B1 (en) | 2006-09-19 | 2013-11-06 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110281908A1 (en) | 2008-10-06 | 2011-11-17 | Emory University | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use |
| KR20200047793A (ko) | 2008-12-09 | 2020-05-07 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | ANTI-GITRANT ANTIBODIES |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| PE20121398A1 (es) | 2009-12-10 | 2012-10-26 | Hoffmann La Roche | Anticuerpos ligantes preferentemente al dominio extracelular 4 de csf1r humano |
| PT2542256T (pt) | 2010-03-04 | 2019-09-05 | Macrogenics Inc | Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918060B (zh) | 2010-03-05 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗人csf-1r抗体及其用途 |
| NZ712765A (en) | 2010-05-04 | 2017-01-27 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
| EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
| HUE041958T2 (hu) | 2010-09-09 | 2019-06-28 | Pfizer | 4-IBB-t kötõ molekulák |
| EP3354640A3 (en) | 2011-04-13 | 2018-10-31 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| NO2694640T3 (sl) | 2011-04-15 | 2018-03-17 | ||
| HUE037651T2 (hu) | 2011-04-20 | 2018-09-28 | Medimmune Llc | B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| CA2853889A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| AR089939A1 (es) | 2012-02-09 | 2014-10-01 | Glenmark Pharmaceuticals Sa | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| KR20200140400A (ko) | 2012-08-31 | 2020-12-15 | 파이브 프라임 테라퓨틱스, 인크. | 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법 |
| US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
| WO2014078637A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
| EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
| ES2883285T3 (es) | 2015-12-17 | 2021-12-07 | Merck Patent Gmbh | Antagonistas de tlr7/8 y sus usos |
| US10946020B2 (en) | 2016-04-06 | 2021-03-16 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| JOP20190086A1 (ar) * | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| NZ754994A (en) | 2016-12-22 | 2022-12-23 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US20200231551A1 (en) | 2017-06-26 | 2020-07-23 | University Of Virginia Patent Foundation | Compositions and uses thereof |
-
2019
- 2019-06-26 HR HRP20230627TT patent/HRP20230627T1/hr unknown
- 2019-06-26 RS RS20230468A patent/RS64285B1/sr unknown
- 2019-06-26 IL IL279730A patent/IL279730B2/en unknown
- 2019-06-26 MX MX2020013373A patent/MX2020013373A/es unknown
- 2019-06-26 EA EA202190137A patent/EA202190137A1/ru unknown
- 2019-06-26 PT PT197401664T patent/PT3814347T/pt unknown
- 2019-06-26 EP EP19740166.4A patent/EP3814347B1/en active Active
- 2019-06-26 CA CA3104647A patent/CA3104647A1/en active Pending
- 2019-06-26 LT LTEPPCT/US2019/039131T patent/LT3814347T/lt unknown
- 2019-06-26 DK DK19740166.4T patent/DK3814347T3/da active
- 2019-06-26 PL PL19740166.4T patent/PL3814347T3/pl unknown
- 2019-06-26 SI SI201930549T patent/SI3814347T1/sl unknown
- 2019-06-26 KR KR1020217002232A patent/KR20210024587A/ko not_active Application Discontinuation
- 2019-06-26 CN CN201980055153.7A patent/CN112585139B/zh active Active
- 2019-06-26 WO PCT/US2019/039131 patent/WO2020006016A1/en unknown
- 2019-06-26 SG SG11202012973RA patent/SG11202012973RA/en unknown
- 2019-06-26 FI FIEP19740166.4T patent/FI3814347T3/fi active
- 2019-06-26 US US17/254,914 patent/US11866430B2/en active Active
- 2019-06-26 HU HUE19740166A patent/HUE062412T2/hu unknown
- 2019-06-26 JP JP2020572994A patent/JP7373512B2/ja active Active
- 2019-06-26 AU AU2019291792A patent/AU2019291792B2/en active Active
- 2019-06-26 BR BR112020026568-3A patent/BR112020026568A2/pt unknown
- 2019-06-26 ES ES19740166T patent/ES2950007T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20230627T1 (hr) | 2023-09-29 |
| PT3814347T (pt) | 2023-07-18 |
| US20210277004A1 (en) | 2021-09-09 |
| FI3814347T3 (fi) | 2023-06-12 |
| RS64285B1 (sr) | 2023-07-31 |
| WO2020006016A1 (en) | 2020-01-02 |
| CA3104647A1 (en) | 2020-01-02 |
| AU2019291792A1 (en) | 2021-02-11 |
| AU2019291792B2 (en) | 2022-09-29 |
| IL279730B1 (en) | 2023-08-01 |
| MX2020013373A (es) | 2021-03-09 |
| KR20210024587A (ko) | 2021-03-05 |
| PL3814347T3 (pl) | 2023-07-24 |
| US11866430B2 (en) | 2024-01-09 |
| EP3814347B1 (en) | 2023-05-03 |
| BR112020026568A2 (pt) | 2021-03-23 |
| EA202190137A1 (ru) | 2021-05-17 |
| JP2021528469A (ja) | 2021-10-21 |
| EP3814347A1 (en) | 2021-05-05 |
| JP7373512B2 (ja) | 2023-11-02 |
| IL279730A (en) | 2021-03-01 |
| CN112585139B (zh) | 2023-12-01 |
| SG11202012973RA (en) | 2021-01-28 |
| ES2950007T3 (es) | 2023-10-04 |
| LT3814347T (lt) | 2023-07-10 |
| IL279730B2 (en) | 2023-12-01 |
| CN112585139A (zh) | 2021-03-30 |
| HUE062412T2 (hu) | 2023-10-28 |
| DK3814347T3 (da) | 2023-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279730A (en) | Naphthyridinone compounds useful as T-cell activators | |
| ZA202100555B (en) | Substituted naphthyridinone compounds useful as t cell activators | |
| IL290965A (en) | Converted pyridopyrimidinonyl compounds for use as t-cell activators | |
| EP3487990A4 (en) | T-CELL COMPOSITIONS FOR IMMUNOTHERAPY | |
| GB201813178D0 (en) | Cell | |
| GB201712733D0 (en) | Methods & cells | |
| SG11202004935UA (en) | Cell culture methods | |
| GB201803079D0 (en) | Cell | |
| GB201819540D0 (en) | T cell modification | |
| ZA202003594B (en) | Robot cell | |
| EP3655523C0 (en) | CELL CULTURE MATERIALS | |
| GB201904971D0 (en) | Cell | |
| HUE066922T2 (hu) | Sejttenyésztési eljárások | |
| GB201906202D0 (en) | Cell | |
| GB201807693D0 (en) | Cell | |
| EP4048783C0 (en) | MODIFIED CELL | |
| GB201816399D0 (en) | Cell | |
| GB201805918D0 (en) | Cell | |
| GB201608764D0 (en) | Novel cell culture | |
| GB2577995B (en) | Cell | |
| GB201919017D0 (en) | Cell | |
| GB201918906D0 (en) | Cell | |
| GB201918908D0 (en) | Cell | |
| GB201907169D0 (en) | Cell | |
| GB201905652D0 (en) | Cell |